

BC PHARMACARE NEWSLETTER

Edition 20-002

March 2, 2020



In this edition

SHINGRIX® VACCINE FOR FNHA CLIENTS	1
FINGOLIMOD COVERAGE CHANGES	2
COLLABORATIVE PRESCRIBING AGREEMENTS: APREPITANT (EMEND®) AND NETUPITANT-PALONOSETRON (AKYNZEO®) .	2
NON-BENEFIT(S).....	3

SHINGRIX® VACCINE FOR FNHA CLIENTS

Effective February 17, 2020, the Shingrix® vaccine is listed on the FNHA Supplementary Drug Formulary that is adjudicated through Pacific Blue Cross (PBC). When administered by a pharmacist to an FNHA client, a \$10 administration fee may be claimed through PBC. Pharmacies can use the non-benefit PIN **66123642** in PharmaNet to claim the administration fee separately from the drug claim and ensure that the claim adjudicates through PBC.

See [FNHA Shingrix® Coverage](#) (PDF, 95 KB) for more information on processing a Shingrix claim.



The PharmaCare Newsletter is published by the Pharmaceutical Services Division to provide information to British Columbia's health care providers.

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.



FINGOLIMOD COVERAGE CHANGES

Recently, PharmaCare adjusted its coverage of fingolimod following the introduction of generic versions of the drug. The brand version, Gilenya®, is now a partial benefit under the Low Cost Alternative program, while full coverage is available only for the generic versions.

Due to its complexity and monitoring requirements, Gilenya had an associated Patient Support Program (PSP). Most of the generics offer similar programs. Unlike other drugs with PSPs (e.g., biologics), the switch from Gilenya to a generic may be initiated at the pharmacy. Switching to a generic fingolimod requires a change in the PSP provider, which can also be initiated at the pharmacy. Pharmacists are encouraged to enroll patients filling prescriptions for fingolimod in a PSP associated with the generic they are dispensing. For more information on PSPs for fingolimod, please contact the appropriate manufacturer:

Sandoz	<ul style="list-style-type: none"> • www.sandoz.ca/en/psp • Tel: 1 888 6-SANDOZ (726369)
PMS	<ul style="list-style-type: none"> • Email: ally@patientassistance.ca
Teva	<ul style="list-style-type: none"> • Fingolimod Support
Apotex	<ul style="list-style-type: none"> • www.apoassist.com
Jamp	<ul style="list-style-type: none"> • www.jampcare.ca/en/
Marcan	<ul style="list-style-type: none"> • Tel: 1 844 918-0957 • Fax: 1 844 751-2446
Mylan	<ul style="list-style-type: none"> • www.mylan.ca • Tel: 1 888 223-0038
Taro	<ul style="list-style-type: none"> • www.taro.ca • Tel: 1 833 618-0571

Patients who may have difficulty paying for the drug before they meet their Fair PharmaCare deductible should be made aware of the [Monthly Deductible Payment Option](#).

COLLABORATIVE PRESCRIBING AGREEMENTS: APREPITANT (EMEND®) AND NETUPITANT-PALONOSETRON (AKYNZEO®)

In the [November 26, 2019 \(Edition 19-011\)](#) BC PharmaCare Newsletter, PharmaCare stated the Collaborative Prescribing Agreement (CPA) for aprepitant (Emend®) would be replaced by a CPA for netupitant-palonosetron (Akynzeo®).

Based on further consultation with BC Cancer, PharmaCare amended its decision such that prescribers will be able to prescribe either aprepitant or netupitant-palonosetron via CPA for the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy.

The CPAs for prescribers who had been previously granted a CPA for aprepitant will be reactivated as of **February 25, 2020**. These prescribers do not need to send in Special Authority requests for aprepitant and do not need to reapply for an aprepitant CPA.

Oncologists and BC Cancer-designated oncology specialists who have no prior CPA are invited to apply for individual specialist exemption. Collaborative Prescribing Agreements for [netupitant-palonosetron](#) and [aprepitant](#) can be found on the Special Authority web pages for both drugs.

NON-BENEFITS

The following product PIN can be used in PharmaNet so the claim adjudicates through Pacific Blue Cross:

PRODUCT	PIN	FORM	CRITERIA
Shingrix® Injection Fee	66123642	Injection	FNHA clients aged 65 to 69

The following products have been reviewed and will not be listed as PharmaCare benefits under the DINs specified:

PRODUCT	DIN	STRENGTH/Form
latanoprost (Monoprost®)	02456230	50 mg/ophthalmic solution
pegfilgrastim (Fulphila™)	02484153	10 mg/prefilled syringe
fluticasone propionate-salmeterol xinafoate (Aermony RespiClick™)	02467895	55 mcg/dry powder for inhalation
	02467909	113 mcg/dry powder for inhalation
	02467917	232 mcg/dry powder for inhalation
fluticasone propionate-salmeterol xinafoate (Arbesda RespiClick™)	02474611	55 mcg/14 mcg/dry powder for inhalation
	02474638	113 mcg/14 mcg/dry powder for inhalation
	02474646	232 mcg/14 mcg/dry powder for inhalation